Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells

Molecular Cancer Therapeutics

Volumn 8, Issue 11, 2009, Pages 3162-3170

  Simonin, Karin ^a   Brotin, Emilie ^a   Dufort, Sandrine ^a   Dutoit, Soizic ^a   Goux, Didier ^a   N'Diaye, Monique ^a   Denoyelle, Christophe ^a   Gauduchon, Pascal ^a   Poulain, Laurent ^a  

^a UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; BH3 PROTEIN; CISPLATIN; PROTEIN BCL XL; PROTEIN MCL 1; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; BCL-X PROTEIN; BENZOPYRANS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; NITRILES; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 70949089720     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0493     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130
2. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-584
3. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005;4:307-320 (Pubitemid 41130944)
4. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
5. Schwartz PS, Hockenbery DM. Bcl-2-related survival proteins. Cell Death Differ 2006;13:1250-1255
6. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003;39:615-647 (Pubitemid 35454076)
7. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-1337 (Pubitemid 46328466)
8. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279
9. Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol 1998;70:398-403. (Pubitemid 28473641)
10. S expression in normal and neoplastic ovarian tissues. Clin Cancer Res 1998;4:517-524
11. L in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005;96:287-295
12. L down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells. Gynecol Oncol 2007;105:31-44.
13. Mohammad R, Giri A, Goustin AS. Small-molecule inhibitors of bcl-2 family proteins as therapeutic agents in cancer. Recent Patents Anticancer Drug Discov 2008;3:20-30. (Pubitemid 351223207)
14. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000;97:7124-7129 (Pubitemid 30431428)
15. An J, Chen Y, Huang Z. Critical upstream signals of cytochrome c release induced by a novel Bcl-2 inhibitor. J Biol Chem 2004;279:19133-19140
16. Chen J, Freeman A, Liu J, Dai Q, Lee RM. The apoptotic effect of HA14-1, a Bcl-2-interacting small molecular compound, requires Bax translocation and is enhanced by PK11195. Mol Cancer Ther 2002;1:961-967
17. Oliver L, Mahe B, Gree R, Vallette FM, Juin P. HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells. Leuk Res 2007;31:859-863 (Pubitemid 46855902)
18. Manero F, Gautier F, Gallenne T, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 2006;66:2757-2764
19. Lickliter JD, Wood NJ, Johnson L, et al. HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. Leukemia 2003;17:2074-2080 (Pubitemid 37428370)
20. Poulain L, Lincet H, Duigou F, et al. Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer 1998;78:454-463 (Pubitemid 28481164)
21. L, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005;19:1294-1305
22. Reiners JJ, Jr., Kessel D. Susceptibility of myelomonocytic leukemia U937 cells to the induction of apoptosis by the non-peptidic Bcl-2 ligand HA14-1 is cell cycle phase-dependent. Cancer Lett 2005;221:153-163 (Pubitemid 40460402)
23. Skommer J, Wlodkowic D, Matto M, Eray M, Pelkonen J. HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells. Leuk Res 2006;30:322-331 (Pubitemid 43053228)
24. Kessel D, Reiners JJ, Jr. Initiation of apoptosis and autophagy by the Bcl-2 antagonist HA14-1. Cancer Lett 2007;249:294-299
25. Maiuri MC, Criollo A, Tasdemir E, et al. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy 2007;3:374-376
26. Certo M, Del GM V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351-365 (Pubitemid 43668734)
27. Hetschko H, Voss V, Horn S, Seifert V, Prehn JH, Kogel D. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol 2008;86:265-272
28. Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003;17:2036-2045 (Pubitemid 37322135)
29. Doshi JM, Tian D, Xing C. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. J Med Chem 2006;49:7731-7739 (Pubitemid 46033664)
30. Shigemasa K, Katoh O, Shiroyama Y, et al. Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas. Jpn J Cancer Res 2002;93:542-550 (Pubitemid 34752911)
31. Lee EF, Czabotar PE, van Delft MF, et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 2008;180:341-355
32. Real PJ, Cao Y, Wang R, et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 2004;64:7947-7953 (Pubitemid 39446928)
33. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007;12:171-185 (Pubitemid 47199122)
34. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10:375-388
35. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-399
36. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007;67:782-791 (Pubitemid 46192219)
37. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67:1176-1183 (Pubitemid 46270776)
38. Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007;109:4441-4449 (Pubitemid 46743414)
39. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 2007;104:19512-19517
40. Kline MP, Rajkumar SV, Timm MM, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007;21:1549-1560
41. Yang-Yen HF. Mcl-1: a highly regulated cell death and survival controller. J Biomed Sci 2006;13:201-204
42. Warr MR, Shore GC. Unique biology of mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008;8:138-147
43. Shimazu T, Degenhardt K, Nur-E-Kamal A, et al. NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev 2007;21:929-941 (Pubitemid 46625642)
44. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007;67:5418-5424 (Pubitemid 46997282)
45. Michels J, Johnson PW, Packham G. Mcl-1. Int J Biochem Cell Biol 2005;37:267-271
46. Inoshita S, Takeda K, Hatai T, et al. Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 2002;277:43730-43734 (Pubitemid 36157790)
47. Brotin E, Meryet-Figuière M, Simonin K, et al. Bcl-x(L) and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis. Int J Cancer, Epub 2009 Jul 24.
48. Yang C, Kaushal V, Shah SV, Kaushal GP. Mcl-1 is downregulated in cisplatin-induced apoptosis, and proteasome inhibitors restore Mcl-1 and promote survival in renal tubular epithelial cells. Am J Physiol Renal Physiol 2007;292:F1710-7.
49. L family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res 2007;13:7191-7198